Of metastatic colorectal cancers that are found to be KRas wild type at codons 12/13, 5% to 15% can harbor BRAF mutations and show resistance to anti-EGFR therapy [46, 47]. This evidence concerns the gene EGFR and metastatic colorectal cancer.